Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.

ABSTRACT:

Background

Dupilumab, a mAb targeting IL-4Rα, improves upper and lower airway symptoms in patients with aspirin-exacerbated respiratory disease (AERD), but the mechanisms leading to clinical improvement are not fully elucidated.

Objective

Our aim was to identify the mechanistic basis of clinical improvement in patients with AERD treated with dupilumab.

Methods

A total of 22 patients with AERD were treated with dupilumab for 3 months for severe asthma and/or chronic rhinosinusitis with nasal polyps. Clinical outcomes were assessed at baseline and at 1 and 3 months after initiation of dupilumab. Nasal fluid, urine, blood, and inferior turbinate scrapings were collected at the 3 time points for determination of mediator levels, cellular assays, and RNA sequencing.

Res

SUBMITTER: Buchheit KM 

PROVIDER: S-EPMC9378638 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature